GenSight Biologics SA (SIGHT) AI Stock Analysis

• Market Cap: €35.41M
• Dividend Yield: N/A
• Average Volume (3M): 284.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: -50.00%
• EPS Growth: 73.05%
• Country: FR
• Employees: 44
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 130,534,000
• 10 Day Avg. Volume: 157,617
• 30 Day Avg. Volume: 284,068
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 10.23
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.40
• Price Target Upside: 48.15% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

GenSight Biologics SA is in a precarious financial position, with ongoing losses and high debt levels. The company's reliance on external financing is a significant risk, despite some positive short-term technical trends. The negative P/E ratio underscores profitability challenges, impacting the overall attractiveness of the stock.

GenSight Biologics SA Business Overview & Revenue Model

Company Description

GenSight Biologics SA is a clinical-stage biotechnology company located in Paris, France. It specializes in the development of gene therapies for the treatment of retinal neurodegenerative diseases and central nervous system disorders. The company's core product candidates are based on its proprietary Mitochondrial Targeting Sequence (MTS) technology platform, which is designed to restore vision in patients suffering from genetic forms of blindness such as Leber Hereditary Optic Neuropathy (LHON).

How the Company Makes Money

GenSight Biologics generates revenue primarily through the development and commercialization of its gene therapy products. The company aims to bring its lead product candidates to market by conducting clinical trials and ultimately obtaining regulatory approval. Revenue streams are expected to come from sales of approved therapies, licensing agreements, and potential collaborations with larger pharmaceutical companies. These partnerships may include upfront payments, milestone payments based on the achievement of specific development and regulatory milestones, and royalties on sales of commercialized products. Significant factors contributing to its earnings include the successful advancement of product candidates through clinical development and gaining approval from health authorities in key markets.

GenSight Biologics SA Financial Statement Overview

Summary

GenSight Biologics SA faces financial difficulties characterized by persistent losses, high leverage, and negative equity. Despite some improvements in revenue and free cash flow, the company's profitability and financial stability remain major concerns.

Income Statement

GenSight Biologics SA has experienced inconsistent revenue trends over the years, with a notable revenue decline in 2021 and subsequent volatility. The gross profit margin is consistently high, but the company faces significant challenges in profitability, as evidenced by consistently negative net income and EBIT margins. The recent year shows improvement in revenue but still struggles with substantial losses, indicating ongoing financial challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is unfavorable due to negative equity, and return on equity is not meaningful under these circumstances. The equity ratio is also negative, highlighting a risky financial position with heavy reliance on debt.

Cash Flow

The cash flow statement indicates negative operating cash flow, but there has been improvement in free cash flow growth in recent years. However, the free cash flow to net income ratio is negative, reflecting ongoing operational challenges. The company relies heavily on financing activities to support its cash flow needs.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.63M	1.27M	2.58M	5.28M	4.39M
	Gross Profit
2.63M	3.00M	2.58M	5.28M	4.39M
	EBIT
-15.81M	-29.70M	-27.84M	-28.13M	-24.93M
	EBITDA
-14.76M	-21.73M	-26.44M	-26.83M	-34.13M
	Net Income Common Stockholders
-14.00M	-26.22M	-27.62M	-28.62M	-34.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.46M	2.13M	10.61M	44.29M	37.94M
	Total Assets
10.76M	9.13M	25.94M	56.65M	47.36M
	Total Debt
19.11M	18.43M	12.65M	12.57M	14.45M
	Net Debt
16.65M	16.29M	2.04M	-31.72M	-23.49M
	Total Liabilities
37.68M	39.83M	41.22M	40.66M	35.69M
	Stockholders Equity
-26.92M	-30.67M	-15.28M	15.99M	11.67M
Cash Flow		Free Cash Flow
-12.94M	-24.67M	-34.01M	-17.17M	-15.05M
	Operating Cash Flow
-12.94M	-24.66M	-33.75M	-17.14M	-15.04M
	Investing Cash Flow
17.00K	209.00K	172.00K	-16.00K	-376.00K
	Financing Cash Flow
13.54M	15.86M	95.00K	23.74M	33.86M

GenSight Biologics SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SIGHT, the sentiment is Positive. The current price of 0.27 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.24, and below the 200-day MA of 0.31, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.54 is Neutral, neither overbought nor oversold. The STOCH value of 73.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:SIGHT.

GenSight Biologics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CARM	76 Outperform	€2.61B	8.34		6.50%	9.85%	12653.45%
VLA	54 Neutral	€527.18M	―	-7.91%	―	10.32%	94.54%
ALCLS	54 Neutral	$99.49M	―	-34.08%	―	5385.24%	78.16%
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
SIGHT	41 Neutral	€35.41M	―		―	-50.00%	73.05%